Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$25.58 USD

25.58
771,637

+0.27 (1.07%)

Updated Aug 26, 2024 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (188 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NextGen (NXGN) Q1 Earnings Lag Estimates, Revenues Down Y/Y

by Zacks Equity Research

NextGen (NXGN) slashes guidance for fiscal 2020 owing to a dismal Q1.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Varian (VAR) expects revenue growth in the range of 9-10% for fiscal 2019.

Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.

What's in the Offing for DexCom's (DXCM) Earnings in Q2?

by Zacks Equity Research

Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.

Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance

by Zacks Equity Research

Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.

Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.

Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines

by Zacks Equity Research

Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.

Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Medidata (MDSO) gains from solid segmental contributions in Q2.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

by Zacks Equity Research

Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.

Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?

by Zacks Equity Research

Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.

Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?

by Zacks Equity Research

Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.

Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?

by Zacks Equity Research

Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.

Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?

by Zacks Equity Research

With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.

What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?

by Zacks Equity Research

Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.

Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates

by Zacks Equity Research

We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.

DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat

by Zacks Equity Research

Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.

    What's in Store for Boston Scientific's (BSX) Q2 Earnings?

    by Zacks Equity Research

    We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.

    Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?

    by Zacks Equity Research

    NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.

    Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?

    by Zacks Equity Research

    Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.

    Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?

    by Zacks Equity Research

    Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.

    Baxter (BAX) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.

    Analytical Instruments to Aid Thermo Fisher (TMO) Q2 Earnings?

    by Zacks Equity Research

    Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.

    What's in the Offing for Cerner's (CERN) Earnings in Q2?

    by Zacks Equity Research

    Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.

    What's in Store for Varian Medical (VAR) in Q3 Earnings?

    by Zacks Equity Research

    Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.

    What's in Store for Align Technology (ALGN) in Q2 Earnings?

    by Zacks Equity Research

    Align Technology (ALGN) is expected to deliver a strong second quarter on continued adoption of Invisalign system.